Anaesthesia recommendations for patients suffering from

**Neuromyelitis optica spectrum disorder**

**Disease name:** Neuromyelitis optica spectrum disorder

**ICD 10:** G36.0

**Synonyms:** Devic's Disease, Devic's Syndrome, Neuromyelitis optica, NMO, NMOSD

Neuromyelitis Optica spectrum disorder refers to a syndrome characterized by recurrent optic neuritis and/or longitudinally extensive transverse myelitis. Having only been recently recognized to be a different clinical entity from multiple sclerosis, there are scant publications regarding appropriate anesthetic and perioperative management of this disease.

Neuromyelitis optica spectrum disorder (NMOSD) is often described as an idiopathic, relapsing, severe demyelinating disease of the central nervous system (CNS) that preferentially affects the optic nerve and spinal cord, although more correctly the pathology reflects an inflammatory astrocytopathy with secondary demyelination. It has recently been recognized as a distinct disease process from multiple sclerosis [1], associated, in most, but not all patients, by the presence of an IgG antibody to aquaporin-4, a water channel found on CNS astrocytes [2]. Patients typically experience repeating bouts of optic neuritis and/or longitudinally extensive myelitis of three or more vertebral segments in length but an area postrema syndrome of sustained nausea and/or hiccups due to medullary involvement is also recognised [3].

---

**Medicine in progress**

- Perhaps new knowledge
- Every patient is unique
- Perhaps the diagnostic is wrong

---

Find more information on the disease, its centres of reference and patient organisations on Orphanet: [www.orpha.net](http://www.orpha.net)
Disease summary

Recently, the diagnosis criteria for NMOSD have been expanded as AQP4-IgG seropositive status is no longer a requirement for NMOSD [4-6]:

**Diagnostic criteria for NMOSD with AQP4-IgG:**
1. At least 1 core clinical characteristic
2. Positive test for AQP4-IgG using best available detection method (cell-based assay strongly recommended)
3. Exclusion of alternative diagnoses

**Diagnostic criteria for NMOSD without AQP4-IgG or NMOSD with unknown AQP4-IgG status:**
1. At least 2 core clinical characteristics occurring as a result of one or more clinical attacks and meeting all of the following requirements
   a. At least 1 core clinical characteristic must be optic neuritis, acute myelitis with longitudinal transverse myelitis lesions (LETM)
   b. Dissemination in space (2 or more different core clinical characteristics)
   c. Fulfillment of additional MRI requirements, as applicable
2. Negative tests for AQP4-IgG using best available detection method, or testing unavailable
3. Exclusion of alternative diagnoses

**Core clinical characteristics:**
1. Optic Neuritis
2. Acute Myelitis
3. Area postrema syndrome: episode of otherwise unexplained hiccups or nausea and vomiting
4. Acute brainstem syndrome
5. Symptomatic narcolepsy or acute diencephalic clinical syndrome with NMOSD-typical diencephalic MRI lesions
6. Symptomatic cerebral syndrome with NMOSD-typical brain lesions

**Additional MRI requirements for NMOSD without AQP4-IgG and NMOSD:**
1. Acute optic neuritis: requires brain MRI showing (a) normal findings or only nonspecific white matter lesions, OR (b) optic nerve MRI with T2-hyperintense lesion or T1-weighted gadolinium-enhancing lesion extending over >1/2 optic nerve length or involving optic chiasm
2. Acute myelitis: requires associated intradmedullary MRI lesion extending over ≥ 3 contiguous segments (LETM) OR ≥ 3 contiguous segments of focal spinal cord atrophy in patients with history compatible with acute myelitis
3. Area postrema syndrome: requires associated dorsal medulla/area postrema lesions
4. Acute brainstem syndrome: requires associated periependymal brainstem lesions

NMOSD is thought to represent less than 1% of all CNS demyelinating diseases in the Caucasian population, but 20-48% of CNS demyelinating disease in certain non-Caucasian
populations, particular in Asia and Africa [7]. Since NMOSD has been shown to have a different pathophysiology than multiple sclerosis, NMOSD has been observed to behave differently. Immunomodulatory treatments that have been shown to help multiple sclerosis have been also shown to be ineffective in NMOSD, while the inverse is true as well [8].

**Typical surgery**

Patients with NMOSD are neither at any particular elevated risk for any type of surgical intervention nor are they likely to require specific surgical therapies as all treatments are focused on modulating the immune system with medication. In severe cases that are refractory to standard medical treatment, autologous hematopoietic stem cell transplantation has been shown to be beneficial, at least for a period of time [9], which would require administration of an anaesthetic.

**Type of anaesthesia**

Both neuraxial and general anaesthetics in patients with NMOSD have been reported in the literature [10-15], with a majority of cases involving pregnant women, although not all. While two of these case reports describe two cases of neuromyelitis optica flares in women after spinal anesthetics [10,11], subsequent case reports have also demonstrated spinal anesthetics that did not have any neurological sequelae. Because the disease has a relapsing nature, it is difficult to know if these case reports are observing coincidental findings and inappropriately inferring a causal relationship between administration of a spinal anesthetic and development of- or relapse of disease.

As the use of regional anesthesia has been shown to be safe in patients with multiple sclerosis [16,17], it is reasonable to think that regional anesthesia is also safe in patients with NMOSD. Although unsupported by any evidence, it also seems reasonable to avoid regional anesthesia only in the instance that the regional anesthetic would require needle placement through any existing lesions during a flare of NMOSD.

**Necessary additional diagnostic procedures (preoperative)**

If a regional anaesthetic is considered during a flare of NMOSD and current symptoms suggest neurological lesions in the same general anatomical area as the administration of the neuraxial anaesthetic, an MRI of the area to ensure avoidance of active NMOSD lesions should strongly be considered. A thorough preoperative neurological examination, including a neurology consultation, is crucial to understanding a patient's current disease process, which will help with any subsequent development of neurological symptoms.

**Particular preparation for airway management**

The presence of NMOSD does not by itself affect airway management in any particular way.
As patients with NMOSD are typically undergoing immunomodulatory treatments, a clear understanding of the patient's immune function to facilitate appropriate irradiation, leukocyte reduction, and cytomegalovirus testing of any donor products.

**Particular preparation for anticoagulation**

The presence of NMOSD does not by itself affect anticoagulation in any particular way.

**Particular precautions for positioning, transport or mobilisation**

Patients with active symptoms of transverse myelitis may have motor and/or sensory deficits, careful attention should be paid to positioning, and assistance with mobilization may be necessary before and after anaesthesia administration.

**Probable interaction between anaesthetic agents and patient’s long-term medication**

Treatment of an NMOSD exacerbation is typically started with high dose intravenous methylprednisolone [18,19]. If initial treatment with methylprednisolone is unsuccessful, plasma exchange is the next line of treatment. In order to prevent bouts of NMOSD from occurring, patients are typically maintained on azathioprine [20], mycophenolate [21], rituximab [22], methotrexate [23], mitoxantrone [24], and oral corticosteroids [25]. Unless anaesthetics have been shown to interact with the above drugs, which currently is not the case, no additional consideration should be necessary.

**Anaesthesiologic procedure**

Patients with NMOSD are likely to have a history of chronic pain related to either optic neuritis and/or transverse myelitis. Whether or not a general, neuraxial or regional anaesthetic is chosen, patients with chronic pain should be offered analgesic and antihyperalgesic therapies; these may include the administration of NMDA antagonists (nitrous oxide, ketamine) perioperatively as reported in a patient with a severe relapse of NMOSD undergoing a cesarean delivery under spinal anesthesia [15]. In this case report, the patient received substantial benefit by the acute addition of 50% nitrous oxide via face-mask to manage a severe hyperalgesic response to viscerally-mediated pain.

**Particular or additional monitoring**

The presence of NMOSD does not by itself suggest any additional monitors be used perioperatively.

**Possible complications**
While one case report suggests a causal relationship between neuraxial anesthesia and the occurrence or flare of NMOSD [10], subsequent reports have not seen this relationship [11-15]. Treatment should be focused on minimizing perioperative inflammation, and taking into account a patients' immune system at the time of care.

### Postoperative care

A thorough postoperative neurological examination is recommended, especially if there are patient-reported changes from the preoperative neurological exam.

### Information about emergency-like situations / Differential diagnostics

*caused by the illness to give a tool to distinguish between a side effect of the anaesthetic procedure and a manifestation of the disease*

There are no specific emergency-like situations in NMOSD, and while a misdiagnosis is unlikely, other demyelinating disease include multiple sclerosis, acute disseminated encephalomyelitis, systemic lupus erythematosus and Behcet disease can have similar presentations [26-28].

### Ambulatory anaesthesia

The presence of NMO does not by itself affect ambulatory care or recovery from anaesthesia, other than management of acute and chronic pain, in any particular way.

### Obstetrical anaesthesia

While there are case reports [10;11;13-15] on the management of parturients with NMOSD, there is also a case series [12] of patients with NMOSD, reporting various findings with the administration of general and regional anaesthesia. In contrast to multiple sclerosis, exacerbations tend to increase in frequency and severity during pregnancy in women with pre-existing NMOSD [12]. While two case reports have suggested a causal relationship between neuraxial anaesthesia and exacerbation or development of NMOSD, subsequent reports have not shown this relationship. Higher risks of relapse have been established in both multiple sclerosis and NMOSD after delivery, and as such, there is a need to determine what may be associated with an anesthetic exposure (which typically occurs right before a delivery) and what is a consequence of delivery itself [29-31]. There is not enough evidence to firmly establish or refute the presence of any type of association.
Literature and internet links

These guidelines have been prepared by:

**Authors**

**Ruth Landau**, Anaesthesiologist, University of Washington, Seattle WA, USA  
rulandau@uw.edu  
**Nathaniel Greene**, Anaesthesiologist, University of Washington, Seattle WA, USA  
nathanielgreene@me.com  

**Peer revision 1**

**Enrico Facco**, Anaesthesiologist, Università di Padova, Italy  
enrico.facco@unipd.it  

**Peer revision 2**

**Todd Hardy**, Neuroimmunology Clinic, Concord Hospital, University of Sydney, Australia  
thardy@med.usyd.edu.au  

Last date of modification: October 2016